GlassScriptPhysician profile
Danielle M Carlin
NPI 1962946509
$855.14
in general payments reported to CMS, 2019-2025
11 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.31 · 2024: $617 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803 · Travel and Lodging: $9.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.87 |
| Travel and Lodging | $9.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $521.75 | 2024 | Neurostar Tms Therapy System |
| Supernus Pharmaceuticals, INC. | $105.54 | 2024-2025 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.19 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.64 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $31.32 | 2024 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $31.06 | 2024 | Airsupra |
| Acadia Pharmaceuticals INC | $20.77 | 2025 | Nuplazid |
| Phadia US INC. | $16.00 | 2025 | Immunocap |
| Lilly USA, LLC | $15.37 | 2025 | Kisunla |
| Novo Nordisk INC | $14.78 | 2021 | |
| Electromed, INC. | $13.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Carlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.